Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
PRISM, 2019 | randomized controlled trial | inadequate or absent control group | phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile. |
Buckley BMC Cancer 2019; 19:1102 10.1186/s12885-019-6273-1 Naveen S. Vasudev JCO 42, 312-323(2024) 10.1200/JCO.23.00236 |